Akebia Therapeut (AKBA) Stock News

Akebia Therapeutics (Nasdaq: AKBA), a biopharmaceutical company focused on kidney disease, has granted stock options to four newly-hired employees as employment inducements. The options total 141,800 shares of common stock with an exercise price of $3.64 per share, matching the closing price on June 30, 2025.

The options will vest over a four-year period, with 25% vesting after the first year and the remaining 75% vesting quarterly thereafter, contingent on continued employment. Each option has a 10-year term and follows Akebia's inducement award program guidelines and Nasdaq Listing Rule 5635(c)(4).

Akebia Therapeutics (AKBA) announced the publication of pre-specified analyses from their vadadustat global Phase 3 clinical program in the Journal of the American Society of Nephrology. The analysis compared vadadustat with darbepoetin alfa in patients with chronic kidney disease (CKD)-related anemia. For dialysis-dependent CKD patients, safety and efficacy were similar between vadadustat and darbepoetin alfa both in and outside the US. However, in non-dialysis-dependent CKD patients, while efficacy was similar, the US subgroup showed higher risk of major adverse cardiovascular events with vadadustat compared to outside the US. Vafseo (vadadustat) received FDA approval in March 2024 for treating anemia in adults with CKD who have been on dialysis for at least three months, and has been available in the US since January 2025.

Akebia Therapeutics (AKBA) has granted stock options to three new employees as part of their employment inducement package. The options total 137,000 shares with an exercise price of $3.03 per share, matching the closing price on May 30, 2025. These options follow a 4-year vesting schedule with 25% vesting after the first year and the remaining 75% vesting quarterly thereafter. The options have a 10-year term and are subject to continued employment with Akebia. The grants were made in accordance with Nasdaq Listing Rule 5635(c)(4) as part of Akebia's inducement award program.

Akebia Therapeutics (NASDAQ: AKBA), a biopharmaceutical company focused on kidney disease treatments, has announced its participation in the upcoming Jefferies Global Healthcare Conference. The company's executive management will engage in a Fireside Chat scheduled for June 5, 2025, at 8:45 AM EDT in New York City. Investors and interested parties can access the webcast presentation through Akebia's investor relations website at ir.akebia.com after the conference concludes. The conference will run from June 3-5, 2025.

Akebia Therapeutics (AKBA) announced three upcoming poster presentations at the 62nd European Renal Association Congress 2025, taking place June 4-7 in Vienna. The presentations will focus on clinical data for vadadustat, their treatment for CKD-related anemia. Key presentations include: a cardiovascular safety analysis of vadadustat in dialysis patients presented by Dr. Glenn Chertow, a study on vadadustat's combination with ferric citrate, and real-world data comparing HIF-PH inhibitors with ESAs in non-dialysis CKD patients from a Japanese database study.

Akebia Therapeutics (NASDAQ: AKBA), a biopharmaceutical company focused on kidney disease treatments, has announced its participation in the upcoming H.C. Wainwright 3rd Annual BioConnect Investor Conference. The company's CEO John Butler and CCO Nik Grund will engage in a Fireside Chat on Tuesday, May 20, 2025, at 2:30 PM EDT at the Nasdaq Headquarters in New York City. Investors can access the presentation webcast through the "Investors" section of Akebia's website after the conference.

Akebia Therapeutics (AKBA) reported strong Q1 2025 financial results, highlighted by the successful U.S. launch of Vafseo® (vadadustat) for anemia in dialysis patients. The company generated $12.0 million in Vafseo net product revenues and total net product revenues of $55.8 million. Over 640 prescribers wrote prescriptions for Vafseo, with each averaging nearly 12 prescriptions. Auryxia® revenues reached $43.8 million. The company strengthened its financial position through a $50 million public offering, ending Q1 with $113.4 million in cash. Akebia reported a net income of $6.1 million, compared to a net loss of $18.0 million in Q1 2024. The company plans to initiate the VALOR Phase 3 trial for vadadustat in non-dialysis CKD patients in H2 2025.

Akebia Therapeutics (NASDAQ: AKBA), a biopharmaceutical company focused on kidney disease treatments, has granted stock options to eight newly-hired employees. The inducement grants total 148,000 shares of common stock with an exercise price of $2.41 per share, matching the closing price on April 30, 2025. The options feature a 4-year vesting schedule with 25% vesting after the first year and the remaining 75% vesting quarterly thereafter. Each option has a 10-year term and is contingent on continued employment with Akebia.

Akebia Therapeutics (NASDAQ: AKBA) has announced it will release its first quarter 2025 financial results on Thursday, May 8, 2025, before market open. The company will host a conference call at 8:00 a.m. EDT on the same day to discuss the financial results and recent business highlights.

Participants are encouraged to dial in 15 minutes before the scheduled start time to ensure timely connection. A live webcast will be available through Akebia's Investors section website, with an online archive accessible afterward at ir.akebia.com.